Agilent Technologies acquired BioTek Instruments (Lionheart Technologies LLC) for approximately $1.17 billion, a transaction completed in August 2019, structured as all cash.
BioTek Instruments (Lionheart Technologies LLC) operates in Life Sciences and Applied Markets, is based in Winooski, Vermont, USA. BioTek Instruments (legal entity Lionheart Technologies LLC) designs, manufactures and distributes life-science instrumentation, including cell-imaging systems, microplate readers, washers, dispensers and automated incubators used in research.
BioTek was Agilent's largest deal since Dako, expanding its cell-analysis franchise into an integrated live-cell analysis solution and strengthening its position in fast-growing immuno-oncology markets; the purchase accounting recorded $387 million of developed product technology.
BioTek represents a strong strategic fit with Agilent. The combination of these two companies will accelerate our multi-year growth strategy to expand our position in cell analysis.Mike McMullen, President and CEO, Agilent
Advisory firms were not disclosed for this transaction.